Selective disruption of MMP-2 gene exacerbates myocardial inflammation and dysfunction in mice with cytokine-induced cardiomyopathy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 5 58-5, 2005, Pages

  Matsusaka, Hidenori ^a   Ikeuchi, Masaki ^a   Matsushima, Shouji ^a   Ide, Tomomi ^a   Kubota, Toru ^a   Feldman, Arthur M ^c   Takeshita, Akira ^a   Sunagawa, Kenji ^a   Tsutsui, Hiroyuki ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Heart failure; Metalloproteinases; Tumor necrosis factor

Indexed keywords

CYTOKINE; GELATINASE A; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; EXTRACELLULAR MATRIX; FEMALE; GENE DISRUPTION; GENE OVEREXPRESSION; HEART DISEASE; HEART FAILURE; HYPOTHESIS; MACROPHAGE; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; ZYMOGRAPHY;

ANIMALS; CARDIOMYOPATHIES; CYTOKINES; ELECTROCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT; MYOCARDITIS; MYOCARDIUM; ORGAN SIZE; RNA, MESSENGER; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27144554066     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00216.2005     Document Type: Article

References (29)

1. Carlyle WC, Jacohson AW, Judd DL, Tian B, Chu C, Hauer KM, Hartman MM, and McDonald KM. Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. J Mol Cell Cardlol 29: 2451-2463, 1997.
2. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, and Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833-1839, 2000.
3. Corry DB, Rishi K, Kanellis J, Kiss A, Song LZ, Xu J, Feng L, Werb Z, and Kheradmand F. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol 3: 347-353, 2002.
4. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, and Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106: 55-62, 2000.
5. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, and McTiernan C. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 35: 537-544, 2000.
6. Funakoshi H, Kubota T, Kawamura N, Machida Y, Feldman AM, Tsutsui H, Shimokawa II, and Takeshita A. Disruption of inducible nitric oxide synthase improves β-adrenergic inotropic responsiveness but not the survival of mice with cytokine-induced cardiomyopathy. Circ Res 90: 959-965, 2002.
7. Haas TL and Madri JA. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 9: 70-77, 1999.
8. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, and Takeshita A. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285: H1229-H1235, 2003.
9. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, and Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5: 1135-1142, 1999.
10. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, and Feldman AM. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-α-induced cardiomyopathy. Circulation 109: 1892-1897, 2004.
11. Ikeuchi M, Tsutsui H, Shiomi T, Matsusaka H, Matsushima S, Wen J, Kubota T, and Takeshita A. Inhibition of TGF-β signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64: 526-535, 2004.
12. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, and Itohara S. Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 272: 22389-22392, 1997.
13. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, and Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 169: 2643-2647, 2002.
14. Kadokami T, McTiernan CF, Kubota T, Frye CS, and Feldman AM. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 106: 589-597, 2000.
15. Kubota T, Bounoutas GS, Miyagishima M, Kadokami T, Sanders VJ, Bruton C, Robbins PD, McTiernan CF, and Feldman AM. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 101: 2518-2525, 2000.
16. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, and Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 81: 627-635, 1997.
17. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, and Feldman AM. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor-α can be modulated by anti-tumor necrosis factor-α therapy. Proc Natl Acad Sci USA 97: 12746-12751, 2000.
18. Li YY, Kadokami T, Wang P, McTiernan CF, and Feldman AM. MMP inhibition modulates TNF-α transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 282: H983-H989, 2002.
19. Li YY, McTiernan CF, and Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 42: 162-172, 1999.
20. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, and Lee RT. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105: 753-758, 2002.
21. Machida Y, Kubota T, Kawamura N, Funakoshi H, Ide T, Utsumi H, Li YY, Feldman AM, Tsutsui H, Shimokawa H, and Takeshita A. Overexpression of tumor necrosis factor-α increases production of hydroxyl radical in murine myocardium. Am J Physiol Heart Circ Physiol 284: H449-H455, 2003.
22. Mann DL and Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105: 897-904, 1994.
23. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, and Lee RT. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99: 3063-3070, 1999.
24. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, and Takeshita A. Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106: 3126-3132, 2002.
25. Siwik DA, Chang DL, and Colucci WS. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86: 1259-1265, 2000.
26. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82: 482-495, 1998.
27. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, and Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97: 1708-1715, 1998.
28. Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, Demmy TL, Schmaltz RA, and Curtis JJ. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 28: 1415-1428, 1996.
29. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, and Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549, 2002.